BioSpace News Archive

Axonics, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that LYNPARZA has been approved in the European Union .

Consistent with its requirements under Regulation FD, Castellum, Inc. (NYSE-American: CTM) provides the following information from CEO Mark Fuller for its shareholders, prospective shareholders, and other stakeholders.

TELA Bio, Inc. today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12th, 2023.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 , at 8:15 a.m. PST.

Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Japan new drug application (JNDA) to the Ministry of Health, Labor and Welfare (MHLW) of Japan for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

AEON Biopharma, Inc. today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine.

Precision Medicine Asia Co., Ltd. and National Cancer Center Hospital East announced the initiation of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia Pacific, a genomic screening platform, which will be integrated with LC-SCRUM-Asia to create an international, large scale lung cancer clinicopathological genomic database for the region.

OKYO Pharma Limited announced that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at the event and online.

A poster presented at the recent ESMO Immuno-Oncology Congress in Geneva demonstrates that the cResponse platform can be applied for the modeling and evaluation of immune modulating drugs in cancer tissue.